Response to: Identification of an immunogenic candidate for the elicitation of severe acute inflammatory reactions (SAIRs) to hylan G-F 20 (multiple letters) [2]

Osteoarthritis and Cartilage

Volumn 13, Issue 12, 2005, Pages 1128-1129

  Burns, Jim W ^a   Kraines, J L ^a   Magilavy, D B ^a   Murray, C W ^a   Richards, S M ^a   Hamburger, Max ^b   Settles, M ^c   Teutsch, J ^c  

^a GENZYME CORPORATION   (United States)

^b Genzyme Corporation ^*  (United States)

^c TGA Sciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYALURONIC ACID; HYALURONIDASE; HYLAN G F 20; PROTEIN;

CHRONIC GRANULOMATOUS DISEASE; CROSS LINKING; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG LABELING; DRUG MECHANISM; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOGENICITY; INFLAMMATION; INJECTION PAIN; KNEE OSTEOARTHRITIS; LETTER; NONHUMAN; PRIORITY JOURNAL;

EID: 27944467390     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2005.07.013     Document Type: Letter

References (4)

1. M. Hamburger M. Settles J. Teutsch Identification of an immunogenic candidate for the elicitation of severe acute inflammatory reactions (SAIRs) to hylan G-F 20 Osteoarthritis Cartilage 15 2005 266 268
2. ® [prescribing information]. New York, NY: Sanofi-Synthelabo, Inc.; Revised July 2001, 07241191.
3. FDA CDRH MAUDE Database
4. M.P. Puttick J.P. Wade A. Chalmers D.G. Connell K.K. Rangno Acute local reactions after intraarticular hylan for osteoarthritis of the knee J Rheumatol 22 1995 1311 1314